Mersana Therapeutics Inc represents core values of innovation, collaboration, and dedication to transforming the lives of cancer patients. As a biopharmaceutical company, Mersana is committed to developing and commercializing innovative antibody-drug conjugates (ADCs) that target and treat various types of cancer. They strive to advance the field of targeted therapies by leveraging their proprietary Fleximer® platform, which allows for precise delivery of potent cancer therapies. Mersana's corporate philosophy centers around scientific excellence and a patient-centric approach, aiming to improve treatment outcomes and quality of life for individuals battling cancer. Their unwavering commitment to research and development fosters a hopeful future in the fight against cancer.

Mersana Therapeutics Inc is primarily present in the United States of America.

Mersana Therapeutics Inc has achieved several significant milestones. The company successfully completed a Phase 1 study for its lead antibody-drug conjugate (ADC) product candidate, XMT-1522, showing promising results in patients with advanced tumors. In addition, Mersana Therapeutics Inc entered into a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize multiple ADCs. The company also announced positive interim data from a Phase 1 study of XMT-1536, its second ADC candidate. Mersana Therapeutics Inc continues to innovate and advance its portfolio of ADC therapies, aiming to address unmet medical needs and improve patient outcomes in oncology.

Mersana Therapeutics Inc is a biopharmaceutical company focused on developing innovative antibody-drug conjugate (ADC) therapies for cancer treatment. Founded in 2001, the company has a strong emphasis on applying its proprietary Fleximer platform technology to deliver highly targeted therapies. Mersana Therapeutics has forged strategic collaborations with renowned companies, including Takeda Pharmaceutical Company, to accelerate the development of ADC therapies. The company's commitment to improving patient outcomes remains steadfast as they continue to advance their pipeline of next-generation ADC candidates targeting various cancers. With a rich history and expertise in the field, Mersana Therapeutics Inc is dedicated to revolutionizing cancer treatment through its cutting-edge therapies.

The main competitors of Mersana Therapeutics Inc in the market include big players such as Amgen Inc., Pfizer Inc., and Merck & Co., Inc. These pharmaceutical companies are also engaged in the development and commercialization of innovative therapeutics, including targeted cancer therapies. Mersana Therapeutics Inc faces competition in terms of technology, patents, research, and financial resources from these established firms in the industry. By continually enhancing their product pipeline and leveraging their unique platform, Mersana Therapeutics Inc aims to differentiate itself and capture a significant share in the competitive market.

Mersana Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Mersana Therapeutics Inc is an innovative biopharmaceutical company primarily focused on developing and commercializing antibody-drug conjugates (ADCs). Their business model revolves around leveraging their proprietary Fleximer® technology platform to design and develop novel ADC candidates for the treatment of various types of cancers. By combining the targeting ability of antibodies with potent anti-cancer drugs, Mersana aims to deliver more effective and safer therapies to patients. With a diverse pipeline of product candidates and collaborations with strategic partners, Mersana Therapeutics Inc aims to advance the field of ADCs and make a meaningful impact in oncology.

مُعامل القيمة السوقية إلى الأرباح لـ Mersana Therapeutics هو ؜-٢٫٨٢.

مُعامِل القيمة إلى المبيعات Mersana Therapeutics هو ٩٫٩٢.

نقاط جودة AlleAktien لـ Mersana Therapeutics هي 3/10.

المتوقعة Mersana Therapeutics الإيرادات هي ٢٥٫٢٨ مليون. USD.

صافي الربح المتوقعة Mersana Therapeutics هو ؜-٨٨٫٩٨ مليون. USD.

Mersana Therapeutics Inc is a biopharmaceutical company focused on the development and production of innovative cancer therapies. The company is headquartered in Cambridge, Massachusetts, USA. Mersana was founded in 2001 and traces its roots back to research conducted at Harvard Medical School. Mersana's business model specializes in the research and development of novel drug candidates for cancer therapy. The company utilizes its own technologies to develop antibody-drug conjugates (ADCs) that specifically target and destroy cancer cells. This involves connecting an antibody that targets specific cancer cells with a toxic drug, which is only released in the cancer cells and is safe for normal body cells. Mersana has several products in its pipeline, including XMT-1536, XMT-1592, and XMT-1660. XMT-1536 is an ADC targeting sodium-dependent phosphate transport protein 2b (NAPT2b), which is overexpressed in many types of cancer. XMT-1592 is an ADC targeting NaPi2b and sodium-dependent phosphate transport protein 2c (NAPT2c), which are frequently found in certain cancer cells like ovarian carcinomas and lung cancers. XMT-1660 is an ADC targeting leukemia inhibitory factor receptor (LIFR), which is aimed at certain solid tumors such as pancreatic cancer and ovarian cancer. Mersana also has partnerships with other pharmaceutical companies and academics to license its technology platform and accelerate the development of cancer therapies. In 2019, Mersana entered into a partnership with Takeda Pharmaceuticals to jointly develop ADCs for four specific solid tumors. In the same year, the company also announced a partnership with the Dana-Farber Cancer Institute to develop multiple novel cancer therapies. Mersana holds several patents for its technology platform, including its Fleximer technology, which enables the targeted release of toxic drugs for cancer therapy. The company has also received various awards for its work, including the Frost & Sullivan Technology Innovation Award for its development of antibody-drug conjugates. The company is listed on the NASDAQ stock exchange under the ticker symbol MRSN. Mersana's funding primarily comes from venture capital firms, including New Enterprise Associates, Fidelity Investments, ArrowMark Partners, and Cormorant Asset Management. Over the years, the company has secured several funding rounds and has several hundred million US dollars available for the further development of its ADCs. In summary, Mersana Therapeutics is a biopharmaceutical company developing innovative cancer therapies based on antibody-drug conjugates. The company has several products in its pipeline and collaborates with other pharmaceutical companies and academics to license and develop its technology platform. Mersana holds various patents for its technology platform and has received several awards for its work. The company is funded by venture capital firms and is listed on the NASDAQ stock exchange.

يوزع Mersana Therapeutics أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Mersana Therapeutics في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـMersana Therapeutics هو US59045L1061.

رمز WKN لـ Mersana Therapeutics هو A2DTR7.

الرمز المُختصر لـ Mersana Therapeutics هو MRSN.

خلال آخر 12 شهراً، دفعت Mersana Therapeutics توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Mersana Therapeutics خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Mersana Therapeutics هي .

Mersana Therapeutics يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Mersana Therapeutics دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Mersana Therapeutics يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Mersana Therapeutics المُعلن عنها في ٢٢‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٢‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٢‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Mersana Therapeutics 0 USD كأرباح أسهم.

يتم توزيع أرباح Mersana Therapeutics بالعملة USD.